Clinical Trials in Denver

Showing 3341-3360 of 15,604 trials

28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

NCT05358821

The primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntington's Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance.

Huntington Disease

Supernus Pharmaceuticals, Inc.69 participantsStarted May 2022

Birmingham, Alabama, United States • Los Alamitos, California, United States • Englewood, Colorado, United States +11 more locations

COMPLETEDPhase 18.4 miles

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

NCT03107988

Lorlatinib is a novel inhibitor across ALK variants, including those resistant to crizotinib. In this first pediatric phase 1 trial of lorlatinib, the drug will be utilized as a single agent and in combination with chemotherapy in patients with relapsed/refractory neuroblastoma. The dose escalation phase of this study (Cohort A1) uses a traditional Phase I 3+3 design. Once a recommended phase 2 pediatric dose is identified, an expansion cohort of 6 patients (Cohort B1), within which ALKi naïve patients will be prioritized, will be initiated. Parallel cohorts will be initiated in adults or patients with large BSA (Cohort A2) and in combination with chemotherapy upon establishing RP2D (Cohort B2).

Neuroblastoma

New Approaches to Neuroblastoma Therapy Consortium65 participantsStarted Sep 2017

Los Angeles, California, United States • San Francisco, California, United States • Aurora, Colorado, United States +10 more locations

28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

Find Trials by Condition in Denver

Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) Deficiency

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Integrated Actionable Aging Assessment for Cancer Patients Pilot

The Pediatric Artificial Pancreas Automated Initialization Trial

Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria

1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.

Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.

A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

Treatment Monitoring in Autism Spectrum Disorder (ASD) in Children

Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older

DFC 004 Biomarkers for Active Diabetic Foot Ulcers

Use of Stromal Vascular Fraction in Multiple Sclerosis

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function

Patient-Directed Antimicrobial Duration in Acute Uncomplicated Pyelonephritis

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)